Recruitment Background:
RC1416 injection, developed εγ♥•by Nanjing RegeneCore BiotechΩα Co.,Ltd, is currently undergoing a ↕ Phase Ib clinical study t↓★o "evaluate the safety, tolerability, pα​harmacokinetics, pharmac±₽₽εodynamics, immunogenicity, and pre÷↔∏liminary effectiveness of RC1416 injection in ↔♦‍patients with moderate to severe asthma." T✘≈¶he lead institution f♦δ✔or this study is the China-Japan Friendship Hosp€ ital in Beijing, and it is simultaneo¶<usly being conducted at dozens of renowned ho‌∑δβspitals across the country.
RC1416 can inhibit the activatio✔≤n of inflammatory pathways an∑ d alleviate asthma symptoms. Cl​​ ©inically, it is intend±↓≥ed for use as an add-on maintenance therapy ® for moderate to severeα→π asthma, meaning that pa₩λ¶✘tients' existing treatment plans remai≠÷±φn unchanged, with RC1416 inject♣‌ion added to their original r♣♠ε egimen.
This study has been approved by the National Me✘₽dical Products Administratioε§→±n and the ethics committees of the partici₩∞pating hospitals. Eligible and vo$€luntary patients will be pr♣ ovided with the study drug, examination §§♠fees stipulated in the study, correspondingδ↕> subsidies that meet regulatory requirements, as≠∑ well as attentive consultat÷σαion and correct medication gui₽→♥∑dance by the project team members.

Inclusion Criteria:
Age: 18 years or older and 75 years or≈"★ younger (inclusive);
Diagnosed with asthma for at least ‍¶"1 year;
Receiving stable treatment with medium-toδα®‍-high doses of inhaleφΩ✔±d corticosteroids (ICS) (e.g., f₽‍Ωluticasone propionate wit ☆∏h a daily dose of ≥2∞★50 μg or an equivalent <φ $dose of ICS) combined with at least one con→♣↔★troller medication [such as long-acting &beta↕♣;2 agonists (LABA), γ"↑​long-acting muscarinic anta∏©gonists (LAMA), leukotriene receptor "™γ↔antagonists (LTRA), or s' low-release theophylline] for at least 3 mont↓∞hs;
FEV1 ≤80% of the predicted value befor÷→e bronchodilator use at screening;
Able to fully understand the ≤♥requirements of this study, comply wi¥≠​th the medication requirements and all study-relλ ®ated procedures and assessments; not consi↓≈ ♦dered potentially unreliable and/or uncoop שerative.

Patients or their famil₩☆ies who wish to learn more ↑↑ε‌can consult the doctors at the∞₹ participating research cente♠™↕'rs. The final decision on eligibility willσδ" be made by the clinicians.